Campto

irinotecan hydrochloride

Campto (UK), Camptosar

Pharmacologic class: Topoisomerase inhibitor

Therapeutic class: Hormonal antineoplastic

Pregnancy risk category D

Action

Inhibits topoisomerase 1 (an enzyme that allows DNA replication) by binding to it. This action prevents religation of DNA strand, which results in breakage of double-stranded DNA and cell death.

Availability

Injection: 20 mg/ml in 2-ml and 5-ml vials

Indications and dosages

Metastatic colorectal cancer or recurrence or progression of metastatic colorectal cancer after fluorouracil (5-FU) therapy

Adults: 125 mg/m2 I.V. infused over 90 minutes on days 1, 8, 15, and 22, followed by a 2-week rest; given with leucovorin and 5-FU. Or, 180 mg/m2 I.V. infused over 90 minutes on days 1, 15, and 29 with leucovorin, 5-FU bolus, and 5-FU infusion followed by a 2-week rest. Or as monotherapy, 125 mg/m2 I.V. infused over 90 minutes weekly for 4 weeks, followed by a 2-week rest period; or, 350 mg/m2 I.V. infused over 90 minutes q 3 weeks as long as tolerable. Adjust dosage in increments based on tolerance and age.

Off-label uses

• Most cancers

Contraindications

• Hypersensitivity to drug
• Concurrent atazanavir use
• Pregnancy or breastfeeding

Precautions

Use cautiously in:
• bone marrow depression, severe diarrhea
• patients undergoing radiation therapy
• elderly patients
• children.

Administration

Follow facility policy for handling antineoplastics. If skin contact occurs, wash with soap and water immediately and thoroughly. If mucous membrane contact occurs, flush with water.
• Dilute in dextrose 5% in water or normal saline solution, to a concentration of 0.12 to 1.1 mg/ml.
• Infuse within 6 hours if drug is stored at room temperature or within 24 hours if refrigerated.
• Give single dose by I.V. infusion over 90 minutes.
• Administer antiemetic to ease nausea and vomiting, as needed and prescribed.

Adverse reactions

CNS: insomnia, dizziness, asthenia, headache, akathisia

CV: vasodilation, orthostatic hypotension

EENT: rhinitis

GI: nausea, vomiting, constipation, diarrhea, flatulence, dyspepsia, abdominal pain or enlargement, stomatitis, anorexia

Hematologic: anemia, neutropenia, leukopenia, thrombocytopenia

Hepatic: hepatotoxicity

Metabolic: dehydration

Musculoskeletal: back pain

Respiratory: dyspnea, increased cough

Skin: alopecia, diaphoresis, rash

Other: weight loss, edema, fever, pain, chills, minor infections

Interactions

Drug-drug.Dexamethasone: increased risk of lymphocytopenia

Diuretics: increased risk of dehydration

Laxatives: increased risk of diarrhea

Other antineoplastics: additive adverse effects

Drug-diagnostic tests.Alkaline phosphatase: increased level

Hemoglobin, neutrophils, white blood cells: decreased values

Patient monitoring

Assess CBC before each infusion. Withhold dose if neutrophil count is below 1,500 cells/mm3.
• Monitor infusion site for extravasation; if it occurs, flush with sterile water and apply ice.
• Assess fluid intake and output. Keep patient well hydrated.
• Monitor oral intake. Evaluate for nausea and vomiting.
• Assess for diarrhea. In severe diarrhea, expect to decrease dosage or withhold dose.
• Institute infection-control protocols to help prevent infection.
• Monitor liver function test results.

Patient teaching

• Inform patient that blood tests will be done before each dose.
• Instruct patient to report pain at infusion site; severe nausea or vomiting; severe, increased, or bloody diarrhea; infection; or injury.

Instruct patient to immediately report unusual tiredness or yellowing of skin or eyes.
• Tell patient that drug increases his risk of infection. Advise him to avoid crowds and other potential infection sources.
• Caution female patient not to breastfeed or become pregnant during therapy. Recommend barrier contraception.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Campto

A brand name for the camptothecin drug IRINOTECAN.
References in periodicals archive ?
Contract notice:GUYANE (973) REMIRE MONTJOLY9oRIMa Tiger campTo AD'AP standards - Pool and carbet Firm slice: ADAP works: pool locker rooms (building No 0050), ADAP works: carbet (building No 0053) Optional slice No 1: Rehabilitation of the pool areas (Building No.
TABLA I NOMBRE, CLAVE, COORDENADAS, ANOS DE OBSERVACION, PROMEDIO DE LA PRECIPITACION TOTAL ANUAL (PP) DE LAS ESTACIONES CLIMATICAS UBICADAS EN EL AREA DE INFLUENCIA DE LA ZONA CANERA EN ESTUDIO Y COEFICIENTE DE VARIACION (CV) Nombre de la estacion Clave Longitud Oeste Latitud Norte (grados) (grados) Villa Tejeda 30364 -96,583 19,000 Acazonica, Paso de Ovejas 30002 -96,583 19,217 El Coyol, Comapa (CFE) 30047 -96,700 19,117 Paso Del Macho 30225 -96,717 18,967 Campto.
Calcium Salt) Eposin Etoposide Injection 20mg/ml Vincristine Vincristine Injection 2mg/2ml in Vial Vincristine Vincristine Injection 10mg/Vial Avastin Bevacizumab Injection 25mg/ml Cisplatin Cisplatin Injection 50mg/Vial Platosin Cisplatin Injection 10mg in 10ml Vial Taxotere Docetaxel Injection 20mg/Vial Glivec Imatinib Capsule 100mg/Capsule Campto Trinotecan Injection 2ml/Vial Paclitaxel Paclitaxel Injection 30mg/5ml in Vial Taxol Paclitaxel Injection 30mg/5ml in Vial Vesanoid Retinoic Acid Capsule 10mg/Capsule Herceptin Trastuzumab Injection 440mg/Vial Tmuran Azathioprine Tablet 50mg/Tablet Cellcept Mycophenolate Tablet 500mg/Tablet Mofetil Neoral Cyclosporin Capsule 25.
Irinotecan (Irinotecan hydrochloride trihydrate) is the generic equivalent of Pfizer's Campto and is a cytostatic, a treatment for advanced colorectal cancer.
Earlier Linford, 50, told campto mates he admired her "perky and peachy bum" adding: "I have been fantasising about Kayla's curves.
Sehr trag tropft >> Campto << in mich rein--/ Ach, war der Stoff doch Chiantiwein
Treatment of colorectal cancer: to sell all of its development, production and marketing activities, in all the countries covered by the licensing contract which Aventis holds for Campto, and in particular all the rights and obligations which Aventis holds under that licence and all other patents and intellectual property rights and/or know-how concerning Campto held by Aventis, including outside the countries covered by the licence.
Yakult Honsha attributed the revision to favorable sales of anticancer drugs Campto and its cost-cutting efforts as well as foreign exchange gains on local currency denominated-borrowings by subsidiaries abroad.
FOLFIRI: 5-fluorouracil (generics), leucovorin (generics) and irinotecan (Pfizer's Camptosar/Campto, Daiichi Sankyo's Topotecin, Yakult Honsha's Campto, generics).
FOLFIRI: 5-fluorouracil (5-FU [generics], leucovorin [folinic acid] [generics], irinotecan [Pfizer's Camptosar/Campo, Daiichi Sankyo's Topotecin, Yakult Honsha's Campto, generics])
FOLFIRINOX: 5-fluorouracil (5-FU, generics), leucovorin (folinic acid, generics), irinotecan (Pfizer's Camptosar/Campto, Daiichi Sankyo's Topotecin, Yakult Honsha's Campto, generics) and oxaliplatin (Sanofi-Aventis's Eloxatin/Eloxatine, Yakult Honsha's Elplat, generics.